ReviewClinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
Introduction
Vaccines are highly effective public health interventions, having saved millions of lives by preventing infectious diseases. The efficacy of a vaccine is determined by the magnitude, duration and quality of the immune response it induces. Depending upon the disease, both the innate and adaptive arms of the immune system may contribute to protection. The innate immune response involves the activation of multiple cell types, including dendritic cells, macrophages, monocytes, neutrophils, basophils, eosinophils, lymphocytes and/or NK cells. The innate immune system provides a rapid response to pathogens, initiates pathogen clearance, and helps in the healing of damaged tissue. Cells of the adaptive immune system include primarily B and T lymphocytes. Adaptive immune responses develop more slowly but are highly specific and therefore critical for providing sterilizing immunity and long-term memory.
Successful vaccination requires a complex series of immune interactions. Professional APCs (dendritic cells and macrophages) as well as certain other immune cells (e.g. B lymphocytes) take up the vaccine Ag. The Ag is then digested and fragments presented to T lymphocytes via cell–cell interactions that require additional surface receptors. Ag-activated CD4 T cells provide help to Ag-specific B cells, supporting their proliferation, switch recombination and somatic hypermutation, resulting in the production of high-affinity Ab (an outcome measured in many clinical trials) [1], [2], [3]. CD8 T cells are also stimulated to proliferate and mature into cytotoxic effectors. These are typically measured by their production of Th1 cytokines, such as IFN-γ. Over the course of the vaccine-elicited response, Ag-specific memory B and T lymphocytes arise that persist long-term and provide protection from subsequent challenge [4], [5], [6], [7].
Toll-like receptors (TLR) belong to the family of pathogen recognition receptors that are triggered by pathogen-associated molecular patterns expressed by bacteria, viruses, fungi and protozoa. The basic structure of these receptors include an extracellular leucine-rich repeat region, a transmembrane domain and a cytosolic Toll/Interleukin-1 receptor domain. TLR stimulation contributes to the induction and maintenance of innate and adaptive immune pathways as well as memory function [3]. Eleven human and 13 mouse TLRs have been identified. These TLRs have been categorized based on their ligand specificity, signal transduction pathways, cellular expression profiles and subcellular localization. While human TLRs 1, 2, 4, 5 and 6 are localized on the cell membrane, TLRs 3, 7, 8, 9 and 10 are embedded in intracellular vesicles [8], [9], although TLR9 was found on the cellular membrane of human CD19+ B cells [10].
TLRs are expressed primarily on immune cells although other cells are known to contribute to host protection, such as barrier epithelial cells, can also express these receptors. Once triggered by pathogen, these cells produce pro-inflammatory cytokines and chemokines that support the recruitment of additional inflammatory mediators, type I interferon and antimicrobial peptides [11]. TLRs are also expressed on malignant cells and may play a role in oncogenesis and tumor progression by influencing the tumor microenvironment [9], [12], [13], [14].
Section snippets
Toll-like receptor 9
TLR9 recognizes the unmethylated CpG motifs present at high frequency in bacterial but rare in mammalian DNA. The TLR9 receptor is localized to in the endoplasmatic reticulum, late endosomal and lysosomal compartments of the intracellular milieu. Thus, internalization of pathogen-derived DNA is required for TLR9 triggering, an outcome that results from either intracellular infection or uptake of bacterial/viral particles by immune cells [15]. Once stimulated, TLR9 initiates a response biased
TLR9-mediated signaling cascade
The binding of CpG DNA to TLR9 induces proteolytic cleavage of the receptor [28], [29]. After exiting the ER, the TLR9 ectodomain is cleaved by asparagine endopeptidase and/or cathepsins [30], [31]. This truncated (rather than full length) form of TLR9 recruits myeloid differentiation factor 88 (MyD88) such that if proteolysis of the receptor is prevented, it becomes non-functional. The requirement for ectodomain cleavage provides an ancillary mechanism to restrict receptor activation to
CpG ODN
Bacterial DNA is the native ligand for TLR9 and synthetic oligonucleotides (ODN) that mimic the structure of bacterial DNA duplicate this activity. In humans, four distinct classes of CpG ODN have been identified based on differences in structure and the nature of the immune response they induce. Although each class contains at least one motif composed of a central unmethylated CG dinucleotide plus flanking regions, they differ in structure and immunological activity.
K-type ODNs (also referred
Anthrax
Anthrax is caused by the toxin-producing gram positive bacterium Bacillus Anthracis. The spores of this pathogen are highly resistant to environmental degradation (desiccation, heat, UV light) and many disinfectant solutions [49]. Protection against anthrax is provided by Abs targeting the ‘protective antigen’ (PA) component of the toxin.
The currently licensed human vaccine, Anthrax Vaccine Adsorbed (AVA) is administered as 6 subcutaneous (SC) injections over 18 months followed by annual
CpG ODN as an adjuvant in HIV-infected individuals
Chronic HIV infection is characterized by latent infection and impairment of CD4 T cells and the cytolytic activity of CD8 T cells. This contributes to a diminution in the immunogenicity of standard vaccines, placing HIV patients at higher risk for associated infections and increased mortality [83], [84]. CpG ODN were found to boost immunity in mice with depressed immune systems. However their utility in HIV-infected patients was uncertain, since they could potentially increase virus
Use of CpG ODN as stand-alone anti-tumor agents
CpG ODN were evaluated as stand alone anti-tumor agents in several clinical trials. While distinct from their use as vaccine adjuvants, results from those trials are described below as they provide insights into the immunostimulatory activity of CpG ODN. Based on the observation that CpG ODN can stimulate an innate immune response capable of decreasing tumor burden in animal models, CpG 7909 alone at doses up to 0.08 mg/kg SQ and 0.32 mg/kg IV was tested in humans. Evidence of in vivo activity
Conclusion and perspectives
This review focuses on the outcome of clinical trials in which CpG ODN were combined with vaccines targeting infectious diseases and cancer. Overall findings indicate that CpG ODN improve humoral and cellular immune responses when vaccines are administered to healthy individuals. CpG ODN accelerated the induction of protective Abs and supported the generation of higher and more persistent Ab titers with protein vaccines. This was best demonstrated by the extensive trials involving vaccines
Conflict of interest
Dr. Klinman and members of his lab have patents related to the use of CpG ODN. All rights to such patents have been assigned to the Federal Government.
References (143)
- et al.
New insights into the regulation of human B-cell differentiation
Trends Immunol
(2009) - et al.
Memories that last forever: strategies for optimizing vaccine T-cell memory
Blood
(2010) - et al.
Functions of toll-like receptors: lessons from KO mice
C R Biol
(2004) - et al.
A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells
Blood
(2003) - et al.
The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells
Blood
(2003) - et al.
Type I interferon in systemic lupus erythematosus and other autoimmune diseases
Immunity
(2006) Pathogen sensors and chemokine receptors in dendritic cell subsets
Vaccine
(2012)- et al.
Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells
Immunity
(2009) - et al.
Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides
J Control Release
(2004) - et al.
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
Adv Drug Deliv Rev
(2009)
Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax
Microbes Infect
Anthrax: an update
Asian Pac J Trop Biomed
Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109
Vaccine
Marked enhancement of the immune response to BioThrax(R) (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers
Vaccine
Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers
Vaccine
CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase
Int Immunopharmacol
CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans
Vaccine
Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations
Vaccine
A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant
Vaccine
Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults
Vaccine
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
Vaccine
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine
Vaccine
Phenotypic and functional heterogeneity of human memory B cells
Semin Immunol
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults
Vaccine
CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
Vaccine
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine
Vaccine
CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells
J Biol Chem
Germinal centres: role in B-cell physiology and malignancy
Nat Rev Immunol
Human marginal zone B cells
Annu Rev Immunol
Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites
PLoS Pathog
Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells
Nat Immunol
Memory CD8 T-cell compartment grows in size with immunological experience
Nature
The evolution of vertebrate Toll-like receptors
Proc Natl Acad Sci USA
Trial Watch: toll-like receptor agonists for cancer therapy
Oncoimmunology
Toll-like receptor 9 can be expressed at the cell surface of distinct populations of tonsils and human peripheral blood mononuclear cells
Infect Immun
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer
Breast Cancer Res Treat
TLR-4 expression and decrease in chronic inflammation: indicators of aggressive follicular thyroid carcinoma
J Clin Pathol
Toll-like receptors and cancer
Nat Rev Cancer
TLR9 signals after translocating from the ER to CpG DNA in the lysosome
Nat Immunol
Therapeutic potential of Toll-like receptor 9 activation
Nat Rev Drug Discov
A Toll-like receptor recognizes bacterial DNA
NAT
Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides
J Immunol
Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity
Cancer Res
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens
J Exp Med
Regulation of B-cell responses by Toll-like receptors
Immunology
Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes
J Leukoc Biol
Pathogen recognition by the innate immune system
Int Rev Immunol
The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor
Nature
Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9
Nat Immunol
Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase
J Exp Med
Cited by (263)
Mechanisms of type I interferon production by chicken TLR21
2024, Developmental and Comparative ImmunologyRevolutionizing medicine with toll-like receptors: A path to strengthening cellular immunity
2023, International Journal of Biological MacromoleculesAminated yeast β-D-glucan for macrophage-targeted delivery of CpG oligodeoxynucleotides and synergistically enhanced cancer immunotherapy
2023, International Journal of Biological MacromoleculesControl of A/D type CpG-ODN aggregates to a suitable size for induction of strong immunostimulant activity
2023, Biochemistry and Biophysics ReportsATP-responsive and functionalized framework nucleic acid for synergistic radio-immunotherapy
2023, Chemical Engineering JournalSmall molecule modulators of immune pattern recognition receptors
2023, RSC Chemical Biology